These 3.8 million Part D enrollees met the clinical criteria, did not have a diagnosis of type 2 diabetes, OSA, or MASH, or a GLP-1 Part D-covered prescription in 2023, and could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026
USD 763.8 million in 2026 to USD 3,280.0 million by 2036 at 15.7% CAGR
Personalized Protocol Your physician prescribes a titration schedule starting low and increasing dose every 4 weeks alongside nutrition and behavior support
Through the NAIC, state insurance regulators establish standards and best practices, conduct peer reviews, and coordinate regulatory oversight
Glucokinase as pancreatic beta cell glucose sensor and diabetes gene